Uspto grants acurx pharmaceuticals new patent for ibezapolstat to treat cdi while reducing recurrence of infection and improving health of the gut microbiome

Staten island, n.y. , july 17, 2024 /prnewswire/ -- acurx pharmaceuticals, inc. (nasdaq: acxp) ("acurx" or the "company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced that a new patent has been granted by the united states patent and trademark office (uspto) on july 16, 2024.
ACXP Ratings Summary
ACXP Quant Ranking